<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36941260</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Affinity maturation generates pathogenic antibodies with dual reactivity to DNase1L3 and dsDNA in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1388</StartPage><MedlinePgn>1388</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1388</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-37083-x</ELocationID><Abstract><AbstractText>Anti-dsDNA antibodies are pathogenically heterogeneous, implying distinct origins and antigenic properties. Unexpectedly, during the clinical and molecular characterization of autoantibodies to the endonuclease DNase1L3 in patients with systemic lupus erythematosus (SLE), we identified a subset of neutralizing anti-DNase1L3 antibodies previously catalogued as anti-dsDNA. Based on their variable heavy-chain (V<sub>H</sub>) gene usage, these antibodies can be divided in two groups. One group is encoded by the inherently autoreactive V<sub>H</sub>4-34 gene segment, derives from anti-DNase1L3 germline-encoded precursors, and gains cross-reactivity to dsDNA - and some additionally to cardiolipin - following somatic hypermutation. The second group, originally defined as nephritogenic anti-dsDNA antibodies, is encoded by diverse V<sub>H</sub> gene segments. Although affinity maturation results in dual reactivity to DNase1L3 and dsDNA, their binding efficiencies favor DNase1L3 as the primary antigen. Clinical, transcriptional and monoclonal antibody data support that cross-reactive anti-DNase1L3/dsDNA antibodies are more pathogenic than single reactive anti-dsDNA antibodies. These findings point to DNase1L3 as the primary target of a subset of antibodies classified as anti-dsDNA, shedding light on the origin and pathogenic heterogeneity of antibodies reactive to dsDNA in SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gomez-Ba&#xf1;uelos</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9730-1851</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yu</LastName><ForeName>Yikai</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0910-145X</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430074, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cashman</LastName><ForeName>Kevin S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paz</LastName><ForeName>Merlin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trejo-Zambrano</LastName><ForeName>Maria Isabel</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bugrovsky</LastName><ForeName>Regina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Youliang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chida</LastName><ForeName>Asiya Seema</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman-Baust</LastName><ForeName>Cheryl A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0001-7977-4698</Identifier><AffiliationInfo><Affiliation>Gene Regulation Section, Laboratory of Molecular Biology and Immunology, National Institute on Aging, Baltimore, MD, 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>Dylan P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Daniel W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-5003-3503</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darrah</LastName><ForeName>Erika</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1119-0279</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1441-5373</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz</LastName><ForeName>I&#xf1;aki</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-4182-587X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade</LastName><ForeName>Felipe</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3415-0704</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA. andrade@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AI147598</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR069569</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AI049660</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI169851</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR069572</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI110483</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="C485421">DNASE1L3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D004706">Endodeoxyribonucleases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Rheumatol. 2023 Jun;19(6):325</RefSource><PMID Version="1">37165087</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004706" MajorTopicYN="N">Endodeoxyribonucleases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>0</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36941260</ArticleId><ArticleId IdType="pmc">PMC10027674</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-37083-x</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-37083-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahman A, Isenberg DA. Systemic lupus erythematosus. N. Engl. J. Med. 2008;358:929&#x2013;939. doi: 10.1056/NEJMra071297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra071297</ArticleId><ArticleId IdType="pubmed">18305268</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnet, F. M. The Clonal Selection Theory Of Acquired Immunity (Vanderbilt University Press, Nashville; 1959).</Citation></Reference><Reference><Citation>Pisetsky DS. Anti-DNA antibodies&#x2013;quintessential biomarkers of SLE. Nat. Rev. Rheumatol. 2016;12:102&#x2013;110. doi: 10.1038/nrrheum.2015.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.151</ArticleId><ArticleId IdType="pubmed">26581343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y, et al. Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas. N. Engl. J. Med. 1983;308:414&#x2013;420. doi: 10.1056/NEJM198302243080802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198302243080802</ArticleId><ArticleId IdType="pubmed">6823251</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, et al. Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J. Autoimmun. 2009;33:270&#x2013;274. doi: 10.1016/j.jaut.2009.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2009.03.011</ArticleId><ArticleId IdType="pmc">PMC2783480</ArticleId><ArticleId IdType="pubmed">19398190</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson C, et al. Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus. J. Immunol. 2013;191:4926&#x2013;4939. doi: 10.4049/jimmunol.1202263.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1202263</ArticleId><ArticleId IdType="pmc">PMC3816606</ArticleId><ArticleId IdType="pubmed">24108696</ArticleId></ArticleIdList></Reference><Reference><Citation>Tipton CM, et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat. Immunol. 2015;16:755&#x2013;765. doi: 10.1038/ni.3175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3175</ArticleId><ArticleId IdType="pmc">PMC4512288</ArticleId><ArticleId IdType="pubmed">26006014</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemekasten G, et al. Novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J. Clin. Investig. 1998;102:754&#x2013;763. doi: 10.1172/JCI2749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI2749</ArticleId><ArticleId IdType="pmc">PMC508938</ArticleId><ArticleId IdType="pubmed">9710444</ArticleId></ArticleIdList></Reference><Reference><Citation>Virachith S, et al. Anti-beta2 -glycoprotein I antibody with DNA binding activity enters living monocytes via cell surface DNA and induces tissue factor expression. Clin. Exp. Immunol. 2019;195:167&#x2013;178. doi: 10.1111/cei.13229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13229</ArticleId><ArticleId IdType="pmc">PMC6330651</ArticleId><ArticleId IdType="pubmed">30368780</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS, Hoch SO, Klatt CL, O&#x2019;Donnell MA, Keene JD. Specificity and idiotypic analysis of a monoclonal anti-Sm antibody with anti-DNA activity. J. Immunol. 1985;135:4080&#x2013;4085. doi: 10.4049/jimmunol.135.6.4080.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.135.6.4080</ArticleId><ArticleId IdType="pubmed">3877763</ArticleId></ArticleIdList></Reference><Reference><Citation>DeGiorgio LA, et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 2001;7:1189&#x2013;1193. doi: 10.1038/nm1101-1189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1101-1189</ArticleId><ArticleId IdType="pubmed">11689882</ArticleId></ArticleIdList></Reference><Reference><Citation>Budhai L, Oh K, Davidson A. An in vitro assay for detection of glomerular binding IgG autoantibodies in patients with systemic lupus erythematosus. J. Clin. Invest. 1996;98:1585&#x2013;1593. doi: 10.1172/JCI118952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI118952</ArticleId><ArticleId IdType="pmc">PMC507591</ArticleId><ArticleId IdType="pubmed">8833907</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefkowith JB, et al. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. J. Clin. Invest. 1996;98:1373&#x2013;1380. doi: 10.1172/JCI118924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI118924</ArticleId><ArticleId IdType="pmc">PMC507563</ArticleId><ArticleId IdType="pubmed">8823302</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan TM, Yu PM, Tsang KL, Cheng IK. Endothelial cell binding by human polyclonal anti-DNA antibodies: relationship to disease activity and endothelial functional alterations. Clin. Exp. Immunol. 1995;100:506&#x2013;513. doi: 10.1111/j.1365-2249.1995.tb03730.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.1995.tb03730.x</ArticleId><ArticleId IdType="pmc">PMC1534478</ArticleId><ArticleId IdType="pubmed">7774063</ArticleId></ArticleIdList></Reference><Reference><Citation>Deocharan B, Qing X, Lichauco J, Putterman C. Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J. Immunol. 2002;168:3072&#x2013;3078. doi: 10.4049/jimmunol.168.6.3072.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.6.3072</ArticleId><ArticleId IdType="pubmed">11884481</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey&#x2019;s end? Rheumatology. 2007;46:1052&#x2013;1056. doi: 10.1093/rheumatology/kem112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kem112</ArticleId><ArticleId IdType="pubmed">17500073</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan A, Buchanan RR, Lew AM, Olsen I, Staines NA. Five groups of antigenic determinants on DNA identified by monoclonal antibodies from (NZB X NZW)F1 and MRL/Mp-lpr/lpr mice. Immunology. 1985;55:75&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1453573</ArticleId><ArticleId IdType="pubmed">2581889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohnishi K, et al. Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. Int. Immunol. 1994;6:817&#x2013;830. doi: 10.1093/intimm/6.6.817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/6.6.817</ArticleId><ArticleId IdType="pubmed">8086372</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA. Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum. 2004;50:866&#x2013;870. doi: 10.1002/art.20103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20103</ArticleId><ArticleId IdType="pubmed">15022329</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, Y. et al. Neutralizing anti-DNase1L3 antibodies derive from autoreactive VH4-34+-B cells and associate with the interferon signature in SLE. Preprint at medRxiv10.1101/2021.06.07.21258180 (2021).</Citation></Reference><Reference><Citation>Hartl J, et al. Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. J. Exp. Med. 2021;218:e20201138. doi: 10.1084/jem.20201138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201138</ArticleId><ArticleId IdType="pmc">PMC8020718</ArticleId><ArticleId IdType="pubmed">33783474</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyel PA. Dnases in health and disease. Dev. Biol. 2017;429:1&#x2013;11. doi: 10.1016/j.ydbio.2017.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2017.06.028</ArticleId><ArticleId IdType="pubmed">28666955</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron WF, et al. Cloning and characterization of an actin-resistant DNase I-like endonuclease secreted by macrophages. Gene. 1998;215:291&#x2013;301. doi: 10.1016/S0378-1119(98)00281-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-1119(98)00281-9</ArticleId><ArticleId IdType="pubmed">9714828</ArticleId></ArticleIdList></Reference><Reference><Citation>Inokuchi S, et al. Homeostatic milieu induces production of deoxyribonuclease 1-like 3 from myeloid cells. J. Immunol. 2020;204:2088&#x2013;2097. doi: 10.4049/jimmunol.1901304.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1901304</ArticleId><ArticleId IdType="pubmed">32188756</ArticleId></ArticleIdList></Reference><Reference><Citation>Napirei M, Ludwig S, Mezrhab J, Klockl T, Mannherz HG. Murine serum nucleases&#x2013;contrasting effects of plasmin and heparin on the activities of DNase1 and DNase1-like 3 (DNase1l3) FEBS J. 2009;276:1059&#x2013;1073. doi: 10.1111/j.1742-4658.2008.06849.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2008.06849.x</ArticleId><ArticleId IdType="pubmed">19154352</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta R, et al. DNase gamma is the effector endonuclease for internucleosomal DNA fragmentation in necrosis. PLoS ONE. 2013;8:e80223. doi: 10.1371/journal.pone.0080223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0080223</ArticleId><ArticleId IdType="pmc">PMC3846476</ArticleId><ArticleId IdType="pubmed">24312463</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisirak V, et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell. 2016;166:88&#x2013;101. doi: 10.1016/j.cell.2016.05.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.034</ArticleId><ArticleId IdType="pmc">PMC5030815</ArticleId><ArticleId IdType="pubmed">27293190</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mayouf SM, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat. Genet. 2011;43:1186&#x2013;1188. doi: 10.1038/ng.975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.975</ArticleId><ArticleId IdType="pubmed">22019780</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbonella A, et al. An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. Lupus. 2017;26:768&#x2013;772. doi: 10.1177/0961203316676382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316676382</ArticleId><ArticleId IdType="pubmed">27821515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilber A, O&#x2019;Connor TP, Lu ML, Karimi A, Schneider MC. Dnase1l3 deficiency in lupus-prone MRL and NZB/W F1 mice. Clin. Exp. Immunol. 2003;134:46&#x2013;52. doi: 10.1046/j.1365-2249.2003.02267.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.2003.02267.x</ArticleId><ArticleId IdType="pmc">PMC1808827</ArticleId><ArticleId IdType="pubmed">12974753</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpas L, et al. Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proc. Natl Acad. Sci. USA. 2019;116:641&#x2013;649. doi: 10.1073/pnas.1815031116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815031116</ArticleId><ArticleId IdType="pmc">PMC6329986</ArticleId><ArticleId IdType="pubmed">30593563</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni C, et al. Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA. Immunity. 2020;52:1022&#x2013;1038.e1027. doi: 10.1016/j.immuni.2020.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.04.015</ArticleId><ArticleId IdType="pmc">PMC7306002</ArticleId><ArticleId IdType="pubmed">32454024</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollars E, et al. Clinical application of a modular genomics technique in systemic lupus erythematosus: progress towards precision medicine. Int. J. Genomics. 2016;2016:7862962. doi: 10.1155/2016/7862962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/7862962</ArticleId><ArticleId IdType="pmc">PMC5021495</ArticleId><ArticleId IdType="pubmed">27656648</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau R, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165:551&#x2013;565. doi: 10.1016/j.cell.2016.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.03.008</ArticleId><ArticleId IdType="pmc">PMC5426482</ArticleId><ArticleId IdType="pubmed">27040498</ArticleId></ArticleIdList></Reference><Reference><Citation>Becht E, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218. doi: 10.1186/s13059-016-1070-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-1070-5</ArticleId><ArticleId IdType="pmc">PMC5073889</ArticleId><ArticleId IdType="pubmed">27765066</ArticleId></ArticleIdList></Reference><Reference><Citation>Han BK, et al. Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus. Lupus Sci. Med. 2020;7:e000382. doi: 10.1136/lupus-2020-000382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000382</ArticleId><ArticleId IdType="pmc">PMC7247402</ArticleId><ArticleId IdType="pubmed">32444416</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108&#x2013;112. doi: 10.1038/nature08460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08460</ArticleId><ArticleId IdType="pmc">PMC2783335</ArticleId><ArticleId IdType="pubmed">19847166</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaussabel D, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008;29:150&#x2013;164. doi: 10.1016/j.immuni.2008.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.05.012</ArticleId><ArticleId IdType="pmc">PMC2727981</ArticleId><ArticleId IdType="pubmed">18631455</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiche L, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014;66:1583&#x2013;1595. doi: 10.1002/art.38628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38628</ArticleId><ArticleId IdType="pmc">PMC4157826</ArticleId><ArticleId IdType="pubmed">24644022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonegio RG, et al. Lupus-associated immune complexes activate human neutrophils in an FcgammaRIIA-dependent but TLR-independent response. J. Immunol. 2019;202:675&#x2013;683. doi: 10.4049/jimmunol.1800300.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800300</ArticleId><ArticleId IdType="pmc">PMC6344272</ArticleId><ArticleId IdType="pubmed">30610165</ArticleId></ArticleIdList></Reference><Reference><Citation>Porat A, et al. DNA-mediated interferon signature induction by SLE serum occurs in monocytes through two pathways: a mechanism to inhibit both pathways. Front. Immunol. 2018;9:2824. doi: 10.3389/fimmu.2018.02824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02824</ArticleId><ArticleId IdType="pmc">PMC6297782</ArticleId><ArticleId IdType="pubmed">30619247</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappione AJ, Pugh-Bernard AE, Anolik JH, Sanz I. Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes. J. Immunol. 2004;172:4298&#x2013;4307. doi: 10.4049/jimmunol.172.7.4298.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.7.4298</ArticleId><ArticleId IdType="pubmed">15034044</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, et al. Correlation of 9G4 idiotope with disease activity in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 1998;57:566&#x2013;570. doi: 10.1136/ard.57.9.566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.57.9.566</ArticleId><ArticleId IdType="pmc">PMC1752742</ArticleId><ArticleId IdType="pubmed">9849317</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg D, Spellerberg M, Williams W, Griffiths M, Stevenson F. Identification of the 9G4 idiotope in systemic lupus erythematosus. Br. J. Rheumatol. 1993;32:876&#x2013;882. doi: 10.1093/rheumatology/32.10.876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/32.10.876</ArticleId><ArticleId IdType="pubmed">7691367</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, et al. 9G4+ autoantibodies are an important source of apoptotic cell reactivity associated with high levels of disease activity in systemic lupus erythematosus. Arthritis Rheum. 2013;65:3165&#x2013;3175. doi: 10.1002/art.38138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38138</ArticleId><ArticleId IdType="pmc">PMC3981458</ArticleId><ArticleId IdType="pubmed">23983101</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter KN, et al. Molecular characterization of a cross-reactive idiotope on human immunoglobulins utilizing the VH4-21 gene segment. J. Exp. Med. 1993;178:1419&#x2013;1428. doi: 10.1084/jem.178.4.1419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.178.4.1419</ArticleId><ArticleId IdType="pmc">PMC2191190</ArticleId><ArticleId IdType="pubmed">8376944</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiokawa D, Tanuma S. Characterization of human DNase I family endonucleases and activation of DNase gamma during apoptosis. Biochemistry. 2001;40:143&#x2013;152. doi: 10.1021/bi001041a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi001041a</ArticleId><ArticleId IdType="pubmed">11141064</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlissel M, Constantinescu A, Morrow T, Baxter M, Peng A. Double-strand signal sequence breaks in V(D)J recombination are blunt, 5&#x2019;-phosphorylated, RAG-dependent, and cell cycle regulated. Genes Dev. 1993;7:2520&#x2013;2532. doi: 10.1101/gad.7.12b.2520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.7.12b.2520</ArticleId><ArticleId IdType="pubmed">8276236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooker DJ, et al. A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA. Nucleic Acids Res. 2012;40:e113. doi: 10.1093/nar/gks334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks334</ArticleId><ArticleId IdType="pmc">PMC3424536</ArticleId><ArticleId IdType="pubmed">22544708</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler TH, Fehr H, Kalden JR. Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur. J. Immunol. 1992;22:1719&#x2013;1728. doi: 10.1002/eji.1830220709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830220709</ArticleId><ArticleId IdType="pubmed">1623920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravirajan CT, et al. Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur. J. Immunol. 1998;28:339&#x2013;350. doi: 10.1002/(SICI)1521-4141(199801)28:01&lt;339::AID-IMMU339&gt;3.0.CO;2-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1521-4141(199801)28:01&lt;339::AID-IMMU339&gt;3.0.CO;2-C</ArticleId><ArticleId IdType="pubmed">9485213</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenstein MR, et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int. 1995;48:705&#x2013;711. doi: 10.1038/ki.1995.341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1995.341</ArticleId><ArticleId IdType="pubmed">7474655</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, et al. High frequency of shared clonotypes in human B cell receptor repertoires. Nature. 2019;566:398&#x2013;402. doi: 10.1038/s41586-019-0934-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0934-8</ArticleId><ArticleId IdType="pmc">PMC6949180</ArticleId><ArticleId IdType="pubmed">30760926</ArticleId></ArticleIdList></Reference><Reference><Citation>Briney B, Inderbitzin A, Joyce C, Burton DR. Commonality despite exceptional diversity in the baseline human antibody repertoire. Nature. 2019;566:393&#x2013;397. doi: 10.1038/s41586-019-0879-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0879-y</ArticleId><ArticleId IdType="pmc">PMC6411386</ArticleId><ArticleId IdType="pubmed">30664748</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellmann U, et al. The evolution of human anti-double-stranded DNA autoantibodies. Proc. Natl Acad. Sci. USA. 2005;102:9258&#x2013;9263. doi: 10.1073/pnas.0500132102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0500132102</ArticleId><ArticleId IdType="pmc">PMC1166593</ArticleId><ArticleId IdType="pubmed">15968001</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojan G, Petri M. Anti-C1q in systemic lupus erythematosus. Lupus. 2016;25:873&#x2013;877. doi: 10.1177/0961203316645205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316645205</ArticleId><ArticleId IdType="pmc">PMC7523495</ArticleId><ArticleId IdType="pubmed">27252264</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugh-Bernard AE, et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J. Clin. Invest. 2001;108:1061&#x2013;1070. doi: 10.1172/JCI200112462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200112462</ArticleId><ArticleId IdType="pmc">PMC200949</ArticleId><ArticleId IdType="pubmed">11581307</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappione A, 3rd, et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J. Clin. Invest. 2005;115:3205&#x2013;3216. doi: 10.1172/JCI24179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI24179</ArticleId><ArticleId IdType="pmc">PMC1242189</ArticleId><ArticleId IdType="pubmed">16211091</ArticleId></ArticleIdList></Reference><Reference><Citation>Madaio MP, Hodder S, Schwartz RS, Stollar BD. Responsiveness of autoimmune and normal mice to nucleic acid antigens. J. Immunol. 1984;132:872&#x2013;876. doi: 10.4049/jimmunol.132.2.872.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.132.2.872</ArticleId><ArticleId IdType="pubmed">6690621</ArticleId></ArticleIdList></Reference><Reference><Citation>Putterman C, Diamond B. Immunization with a peptide surrogate for double-stranded DNA (dsDNA) induces autoantibody production and renal immunoglobulin deposition. J. Exp. Med. 1998;188:29&#x2013;38. doi: 10.1084/jem.188.1.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.188.1.29</ArticleId><ArticleId IdType="pmc">PMC2525538</ArticleId><ArticleId IdType="pubmed">9653081</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollars E, et al. BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. Lupus Sci. Med. 2015;2:e000063. doi: 10.1136/lupus-2014-000063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000063</ArticleId><ArticleId IdType="pmc">PMC4477150</ArticleId><ArticleId IdType="pubmed">26113988</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 2005;353:2550&#x2013;2558. doi: 10.1056/NEJMoa051135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa051135</ArticleId><ArticleId IdType="pubmed">16354891</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J. Rheumatol. 1992;19:53&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1556700</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith K, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 2009;4:372&#x2013;384. doi: 10.1038/nprot.2009.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.3</ArticleId><ArticleId IdType="pmc">PMC2750034</ArticleId><ArticleId IdType="pubmed">19247287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharm. Stat. 2011;10:128&#x2013;134. doi: 10.1002/pst.426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pst.426</ArticleId><ArticleId IdType="pubmed">22328315</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber W, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods. 2015;12:115&#x2013;121. doi: 10.1038/nmeth.3252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3252</ArticleId><ArticleId IdType="pmc">PMC4509590</ArticleId><ArticleId IdType="pubmed">25633503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Raudvere U, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update) Nucleic Acids Res. 2019;47:W191&#x2013;W198. doi: 10.1093/nar/gkz369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz369</ArticleId><ArticleId IdType="pmc">PMC6602461</ArticleId><ArticleId IdType="pubmed">31066453</ArticleId></ArticleIdList></Reference><Reference><Citation>Domaszewska T, et al. Concordant and discordant gene expression patterns in mouse strains identify best-fit animal model for human tuberculosis. Sci. Rep. 2017;7:12094. doi: 10.1038/s41598-017-11812-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-11812-x</ArticleId><ArticleId IdType="pmc">PMC5608750</ArticleId><ArticleId IdType="pubmed">28935874</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu ZG, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847&#x2013;2849. doi: 10.1093/bioinformatics/btw313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw313</ArticleId><ArticleId IdType="pubmed">27207943</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai R, Winand R, Verbeiren T, Moere AV, Aerts J. dendsort: modular leaf ordering methods for dendrogram representations in R. F1000Res. 2014;3:177. doi: 10.12688/f1000research.4784.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.4784.1</ArticleId><ArticleId IdType="pmc">PMC4162509</ArticleId><ArticleId IdType="pubmed">25232468</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>